---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-22-000026"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:52:02.192915+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q1 revenue $114.5M (+8% YoY); net loss widens to $42.4M; FY22 guidance maintained

## Summary
- Revenue $114.5M, up 8% YoY from $105.8M; gross margin fell to 78% from 84%.
- Net loss $42.4M vs $11.6M in Q1 2021; operating loss $41.7M including $26.0M stock-based comp.
- Operating expenses rose 32% to $130.8M driven by higher personnel, R&D, and infrastructure costs.
- Cash and marketable securities $539.3M as of March 31, 2022.
- Full-year 2022 revenue guidance maintained at $600M-$630M, implying 22-28% growth.

## SEC filing metadata
- accession: 0001770787-22-000026
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000026/0001770787-22-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000026/txg-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-22-000026
- JSON: https://secwatch.observer/filing/0001770787-22-000026.json
- Plain text: https://secwatch.observer/filing/0001770787-22-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.